Related Experiment Video

Updated: May 22, 2026

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays
13:22

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays

Published on: October 23, 2019

Inhibitors of the anaplastic lymphoma kinase

Luca Mologni1

  • 1University of Milano-Bicocca, Monza, Italy. luca.mologni@unimib.it

Expert Opinion on Investigational Drugs
|May 23, 2012
PubMed
Abstract

Insights

Targeted therapies like ALK inhibitors offer a revolutionary approach to treating anaplastic lymphoma kinase-positive cancers. Crizotinib and emerging potent inhibitors demonstrate significant promise for improved patient outcomes.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Anaplastic lymphoma kinase (ALK) is a receptor tyrosine kinase implicated in cancers like ALCL and NSCLC.
  • Current treatments for ALK-driven cancers involve surgery and cytotoxic agents with limited efficacy and high toxicity.
  • Novel small-molecule ALK inhibitors are emerging as promising therapeutic options.

Purpose of the Study:

  • To review ALK inhibitors that have entered clinical investigation.
  • To summarize data on crizotinib's pharmacokinetics, safety, and efficacy.
  • To discuss preliminary data for second-generation ALK inhibitors and address drug resistance.

Main Methods:

  • Comprehensive literature search for ALK inhibitors in clinical trials.
  • Review of published research articles and meeting abstracts.
  • Analysis of pharmacokinetic, safety, and efficacy data for crizotinib and newer compounds.

Main Results:

  • Crizotinib has been approved for ALK-positive tumors.
  • Second-generation ALK inhibitors show increased potency and potential to overcome resistance.
  • Targeted ALK inhibition represents a paradigm shift in cancer therapy.

Conclusions:

  • Targeted therapies based on specific genetic alterations, like ALK inhibitors, are transforming cancer treatment.
  • Crizotinib and upcoming ALK inhibitors offer a new era of precision medicine for ALK-positive malignancies.
  • These targeted agents exemplify the success of personalized medicine in oncology.

More Related Videos

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries08:49

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

Published on: January 22, 2019

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
Anaphase Promoting Complex00:50

Anaphase Promoting Complex

The stepwise destruction of specific proteins is necessary for the progression and completion of the cell cycle. Such proteins are ubiquitinated by ubiquitin ligases and then subsequently destroyed by the proteasome. The SCF (Skp1/Cullin/F-box) and the anaphase-promoting complex (APC) are two important ubiquitin ligases involved in cell cycle progression. While SCF is active throughout the cell cycle, APC gets activated during metaphase to anaphase transition. Cdc20 or Cdh1 binds to APC and...